Related Experiment Video
Updated: Feb 12, 2026

Neutrophil Extracellular Traps: How to Generate and Visualize Them
Published on: February 24, 2010
Neutrophil extracellular traps promote lipopolysaccharide-induced airway inflammation and mucus hypersecretion in
Yong Zou1, Xi Chen2, Jian Xiao3
1Department of Emergency Medicine, Xiangya Hospital of Central South University, Changsha, China.
Abstract:
Bacterial lipopolysaccharide (LPS) contributes to airway inflammation and mucus hypersecretion in chronic airway inflammatory diseases, such as chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF). Neutrophil extracellular traps (NETs) are extracellular meshworks composed of DNA fibers and antimicrobial proteins. Although NET formation has been detected in COPD and CF patients, how NETs contribute to these diseases is poorly understood. This study was performed to clarify the effects and mechanisms of action of NETs in airway inflammation and mucus hypersecretion. We created a murine model of LPS-induced airway inflammation and mucus hypersecretion, and found that LPS-induced NET formation was degraded by aerosolized DNase I treatment in mice. Degradation of NETs by aerosolized DNase I reduced LPS-induced airway inflammation and mucus hypersecretion in mice, this reduction correlated with suppression of TLR4/NF-κB signaling pathway. More importantly, NETs promoted LPS-induced production of IL-1β, IL-6 and TNF-α in macrophages. These results suggest NET degradation using aerosolized DNase I is a potential new therapeutic strategy for treating COPD and CF.
Insights
Bacterial lipopolysaccharide (LPS) triggers airway inflammation and mucus. Degrading neutrophil extracellular traps (NETs) with DNase I reduced these symptoms by inhibiting the TLR4/NF-κB pathway, suggesting a new therapy for COPD and CF.
Area of Science:
- Immunology
- Pulmonology
- Cell Biology
Background:
- Bacterial lipopolysaccharide (LPS) exacerbates airway inflammation and mucus production in chronic airway diseases like COPD and CF.
- Neutrophil extracellular traps (NETs), while antimicrobial, are implicated in disease pathogenesis but their precise role in airway inflammation and mucus hypersecretion remains unclear.
Purpose of the Study:
- To investigate the role of NETs in LPS-induced airway inflammation and mucus hypersecretion.
- To elucidate the underlying mechanisms by which NETs contribute to these conditions.
- To evaluate aerosolized DNase I as a potential therapeutic strategy targeting NETs.
Main Methods:
- A murine model of LPS-induced airway inflammation and mucus hypersecretion was established.
- The effect of aerosolized DNase I on LPS-induced NET formation was assessed.
- Changes in airway inflammation, mucus production, and the TLR4/NF-κB signaling pathway were analyzed.
- The impact of NETs on macrophage-mediated cytokine production (IL-1β, IL-6, TNF-α) was examined.
Main Results:
- LPS-induced NET formation was effectively degraded by aerosolized DNase I in mice.
- DNase I treatment significantly reduced LPS-induced airway inflammation and mucus hypersecretion.
- The reduction in inflammation and mucus correlated with the suppression of the TLR4/NF-κB signaling pathway.
- NETs were found to promote LPS-induced production of pro-inflammatory cytokines IL-1β, IL-6, and TNF-α by macrophages.
Conclusions:
- NETs play a significant role in promoting airway inflammation and mucus hypersecretion in response to LPS.
- Degradation of NETs using aerosolized DNase I effectively ameliorates these LPS-induced responses.
- Inhibition of the TLR4/NF-κB pathway is a key mechanism underlying the therapeutic effect of DNase I.
- Aerosolized DNase I represents a promising therapeutic strategy for managing chronic airway inflammatory diseases such as COPD and CF.
More Related Videos
Related Concept Videos
Inflammation
Social Traps
Formation of Lipopolysaccharides
The Eukaryotic Promoter Region
The Eukaryotic Promoter Region
Suctioning the Nasopharyngeal Airway
Equipment Required

